REGENXBIO shares fell over 29% after the U.S. Food and Drug Administration placed a clinical hold on two experimental gene therapies, RGX-111 and RGX-121. The move followed the detection of a tumor during a routine MRI in a pediatric trial participant, who had received RGX-111 four years earlier.